YMAB
Y-Mabs Therapeutics Inc

697
Loading...
Loading...
News
all
press releases
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·11d ago
News Placeholder
More News
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
Latest Ratings for YMAB DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Jan 2022JP MorganMaintainsNeutral Nov 2021JP MorganDowngradesOverweightNeutral View More Analyst Ratings...
Benzinga·1y ago
News Placeholder
Y-mAbs Therapeutics Finalizes CFO Transition and Advisory Deal
Y-Mabs Therapeutics (YMAB) has issued an update. Y-mAbs Therapeutics, following the resignation of Executive VP and CFO Bo Kruse, has finalized a s...
TipRanks Financial Blog·1y ago
News Placeholder
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CalciMedica (CALC Research Report) and Y-Mabs Therapeutics...
TipRanks Financial Blog·1y ago
News Placeholder
Y-mAbs Therapeutics (YMAB, $16.19) Stochastic Oscillator left the overbought zone on April 01, 2024
This is a signal that YMAB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
Tickeron - Stocks·1y ago

Latest YMAB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.